Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
HMPL-415S1 · 1 trial · 1 indication
Occurrence of Dose Limiting Toxicities (DLTs) During the DLT Observation Period
| Arm | Type | Description |
|---|---|---|
| HMPL-415S1 | EXPERIMENTAL | HMPL-415S1 will be administered orally once daily in 28 days treatment cycles |
| Name | Type | Description |
|---|---|---|
| HMPL-415S1 | DRUG | HMPL-415S1 will be supplied as 0.5 mg, 5 mg and 25 mg capsules |
Inclusion Criteria: All the following conditions must be met for enrollment: 1. Fully understand this study and voluntarily sign the ICF; 2. Dose escalation Patients with advanced malignant solid tumor confirmed by histopathology or cytology, who have failed, been intolerant or unavailable to, or ...
HMPL-415S1 is an investigational small molecule being studied for the treatment of advanced malignant solid tumors. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
HMPL-415S1 targets SHP2, a protein tyrosine phosphatase involved in cell signaling pathways. By inhibiting SHP2, the drug aims to disrupt signaling that can promote tumor growth in advanced solid tumors.
HMPL-415S1 is being developed by HUTCHMED (China) Limited, a biopharmaceutical company listed on the stock exchange under the ticker HCM.
HMPL-415S1 is in Phase 1 clinical development. It is an investigational drug and has not received FDA approval. The ongoing trial is recruiting patients with advanced malignant solid tumors in China.
HMPL-415S1 is being evaluated in a Phase 1 clinical trial with the identifier NCT05886374. This open-label, uncontrolled study is recruiting approximately 81 adult patients with advanced malignant solid tumors in China.
HMPL-415S1 is a specific SHP2 inhibitor, meaning it is designed to block the activity of the SHP2 protein. It is one of several investigational drugs in this class, but it is a distinct compound developed by HUTCHMED.